• This email address is being protected from spambots. You need JavaScript enabled to view it.
  • Sun - Fri 8:00 - 20:30
The 'Press Releases' section offers the latest product-specific and company-related updates to our esteemed clients, providing them with a valuable resource. Members can leverage this platform for quick, efficient, and effective visibility.

— Our press release programs complement our content distribution initiatives, ensuring strong positioning across major media outlets and social media channels. This enhances the visibility of your message within the global pharmaceutical industry.
Libtayo

At five years, Libtayo® (cemiplimab) plus chemotherapy results reinforce significant and durable improvements in survival outcomes for advanced non-small cell lung cancer

Regeneron Pharmaceuticals, Inc. announced five-year follow-up results on overall survival (OS) from the Phase 3 EMPOWER-Lung 3 trial, which evaluated Libtayo® (cemiplimab) plus platinum-based chemotherapy versus chemotherapy alone as a first-line treatment for adults with locally advanced or metastatic non-small cell lung cancer (NSCLC) with no EGFR, ALK or ROS1 aberrations.

Read more →
 MiniMed™ 780G system

FDA clears MiniMed™ 780G system for integration with Abbott's Instinct sensor and approves its use in type 2 diabetes

Medtronic plc a global leader in healthcare technology, announced two U.S. Food and Drug Administration (FDA) regulatory milestones that broaden the MiniMed™ 780G system portfolio: clearance of the SmartGuard™ algorithm as an interoperable automated glycemic controller (iAGC), enabling integration with the Instinct sensor, made by Abbott, for type 1 diabetes, and approval of the MiniMed™ 780G system for use in adults 18+ with insulin-requiring type 2 diabetes.

Read more →
Phase 3 Trial of 2-Dose Varicella Vaccine

SK bioscience submits IND for Phase 3 trial of 2-dose varicella vaccine, reflecting global standard shift

SK bioscience, a global innovative vaccine and biotech company committed to promoting human health from prevention to cure, announced that it has submitted an IND (Investigational New Drug application) to the Ministry of Food and Drug Safety for a global Phase 3 clinical trial of SKYVaricella to add the 2-dose (two-shot) indication, aligning with evolving international standards that increasingly recommend two doses to provide stronger, longer-lasting protection against varicella.

Read more →
Ozempic® and Wegovy

To expand access to Ozempic® and Wegovy®, GoodRx has partnered with Novo Nordisk, offering them for $499 per month

GoodRx (Nasdaq: GDRX), the leading platform for medication savings in the U.S., announced that via a collaboration with Novo Nordisk, all strengths of Ozempic® (semaglutide) and Wegovy® (semaglutide) pens are available to eligible self-paying patients for $499-per-month through GoodRx, effective today.

Read more →
PicoIV CBD

PICO IV Forms Strategic Partnership with Liquivida and Appoints Sam Tejada as Spokesperson

PICO IV, the pioneers behind the world's first sterile CBD emulsion, have announced a strategic partnership with Liquivida®, a national leader in IV therapy and wellness. This partnership marks an exciting turn for both companies as they continue to innovate in IV hydration while upholding the highest standards of safety and education.

Read more →
microneedle patch developed by Daewoong Therapeutics

Daewoong Therapeutics' microneedle patch achieves best-in-class bioavailability, demonstrating the strength of its drug-delivery platform

Daewoong Pharmaceutical (Co-CEOs Seong-Soo Park and Chang-Jae Lee) and Daewoong Therapeutics (CEO Bok-Ki Kang) announced that their proprietary semaglutide microneedle patch achieved more than 80%relative bioavailability compared to the injectable formulation in a pilot human pharmacokinetic study.

Read more →
Modeyso

Jazz Pharmaceuticals announces the U.S. FDA approval of Modeyso™ (dordaviprone) as the first and only treatment for recurrent H3 K27M-mutant diffuse midline glioma

Jazz Pharmaceuticals plc announced that the U.S. Food and Drug Administration (FDA) has granted accelerated approval for Modeyso™ (dordaviprone) for the treatment of adult and pediatric patients 1 year of age and older with diffuse midline glioma harboring an H3 K27M mutation with progressive disease following prior therapy.1 Continued approval for this indication may be contingent upon verification and description of clinical benefit in the Phase 3 ACTION confirmatory trial.

Read more →
Planova™ S20N Virus Removal Filters

Asahi Kasei strengthens Life Science’s global bioprocess supply capabilities by expanding Planova™ production with a new spinning plant

Asahi Kasei Life Science, a division of diversified global manufacturer Asahi Kasei, announced plans to construct a new spinning plant for its Planova™ virus removal filters in Nobeoka City, Miyazaki, Japan. The new facility will be the company’s fourth spinning plant for hollow-fiber cellulose membrane filters.

Read more →
 CURECA™

Seegene unveils the world's first unattended PCR automation, igniting a global diagnostic paradigm shift

Seegene Inc., a global leader in molecular diagnostics, announced that it will unveil its fully automated PCR testing system, CURECA™, and its data analytics platform, STAgora™, at ADLM 2025 (Association for Diagnostics & Laboratory Medicine), the world's largest diagnostics conference, taking place in Chicago from July 28 to 31. With the introduction of these new technologies, Seegene declares a transformative shift in the global diagnostics paradigm.

Read more →